A trivalent parainfluenza virus vaccine has been tested in guinea pigs. The parainfluenza 2 virus vaccine component was superior in the magnitude of antibody titers, and in the ability to convert animals serologically after two doses of an undiluted or a 10-fold diluted vaccine. The parainfluenza 1 virus vaccine gave a higher percentage of conversion than parainfluenza 3 virus vaccine after adm...

The ability to rescue an infectious, recombinant, negative-stranded, RNA virus from a complementary DNA (cDNA) clone, has led to new opportunities for measuring viral replication from a viral expressed reporter gene. In this study, the enhanced green fluorescent protein (EGFP) gene was inserted into the human parainfluenza virus type 3 (HPIV-3) antigenome and a recombinant, infectious virus was...

A phase 2 clinical trial was conducted to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young infants. Three groups were tested as follows: placebo (n=66) and 10(5) (n=64) or 10(6) (n=62) TCID(50) of bPIV3. The vaccine or placebo was administered intranasally at ages 2, 4, 6, and 12-15 months, and serum specimens were collected at ages 2, 6, 7, 12-1...

The sequence variation in a 934 base-pair region of the gene encoding the haemagglutinin-neuraminidase of five human parainfluenza virus type 3 (HPIV3) isolates was determined together with that of a prototype UK strain. All of the clinical isolates were from the Manchester area of the UK and were obtained in 1990, 1991 and 1993. The gene segment was amplified by the polymerase chain reaction u...